Macular Edema Treatment Market Size, Share and Global Trend By Type (Diabetic Macular Edema, Cystoid Macular Edema), By Treatment Type (Anti-VEGF (Vascular Endothelial Growth Factor) Injections, Anti-inflammatory Medications, Corticosteroids), By End User (Hospitals, Ophthalmic Care Institutions, Ambulatory Surgery Centres) and Regional Forecast, 2024-2032

In July 2018, ThromboGenics, Belgium based biotechnology company completed its first clinical trial of an antibody (THR-317) for the treatment of macular edema. Macular edema is an ophthalmic condition where the fluid builds up in the macula, an area in the center of the retina. Retina refers to the light-sensitive tissue or the sensory membrane that lines the inner layer at the back of the eyeball.

Retina enables the conversion of the light signals the lens receives to neural signals and the sending of these signals to the brain for visual recognition. The macula is a small but crucial area and is positioned in the center of the retina, enabling the clearer sight of details of objects such as faces and text. Macular edema can be classified into two types: diabetic macular edema and cystoid edema.

Macular Edema can be caused due to diabetes, uveitis, retinal vein occlusion, aging, hereditary diseases, toxicity, trauma and after the undertaking of cataract surgery. The symptoms of macular edema include wavy or blurred vision, double vision, floaters and may lead to blindness if left untreated. Macular edema can be treated in a number of ways such as management of blood sugar, surgical procedures, corticosteroid treatments and anti-VEGF injections amongst others.

The global macular edema treatment market is anticipated to grow, owing to a number of factors such as the increasing prevalence of eye disorders such as various forms of macular edema and increasing incidence of diabetes leading to a greater incidence of diabetes macular edema.

Moreover, increasing research & developments in treatment options, rising emphasis on preventive medical care through regular eye examinations and increasing awareness regarding eye health is anticipated to offer favorable environment for the growth of the global macular edema treatment market during the forecast period.

According to the Centres for Disease Control and Prevention (CDC), in 2015, an estimated 30.3 million Americans, or 9.4% of the population, had diabetes and out of which an estimated 1.25 million American children and adults were suffering from type 1 diabetes.

Some of the factors limiting the growth of the global macular edema treatment market are the lack of awareness of the disease and the treatment options.

Key Players Covered

Some of the major companies that are present in the global macular edema treatment market are F. Hoffmann-La Roche Ltd, Alimera Sciences, Inc., Allergan, Novartis AG, GlaxoSmithKline plc., and Bausch Health Companies Inc., and others.

SEGMENTATION

Among the segmentation, diabetic macular edema in the type segment is expected to hold significant share of the market owing to higher prevalence of diabetic macular edema. Additionally, Anti-VEGF injections among treatment type segment is projected to register significant CAGR owing to its higher adoption due to its efficiency in treating macular edema.

Key Insights

• The regulatory scenario for key countries


• Reimbursement scenarios for key countries


• Epidemics of Macular Edema for key countries


• Recent industry developments such as partnerships, mergers, and acquisitions

Regional Analysis

North America is projected to dominate the global macular edema treatment market due to the increasing prevalence of ophthalmic diseases such as macular edemas, established healthcare system, high healthcare expenditure, and access to advanced technologies. The Asia Pacific is to exhibit the fastest emerging market due to increasing incidence and awareness of ophthalmic disorders and increasing access to advanced technologies. Combined with this, increasing patient population, gradual shift of patients towards early disease diagnosis and growing per capita expenditure in emerging nations are expected to offer a significant environment for the growth of the macula edema market in the Asia Pacific.

Key Industry Developments

• In December 2018, Clearside Biomedical submitted new medication, XIPERE, for the treatment of macular edema associated with Uveitis.
• In July 2014, Eylea injection, formulated by Regeneron Pharmaceuticals, Inc., received FDA approval for the treatment of diabetic macular edema.